Investigation of Genetic Markers for Predicting Oral Cancer Progression and Patient Outcomes

• Published in: Journal of pharmacy & bioallied science Vol. 16; no. Suppl 3; pp. S2129 - S2131
• Main Authors: Wasti, Amit, Mohanty, Liza, Shukla, Ruchira, Gupta, Bharti, Gowdar, Inderjit Murugendrappa, Mehta, Tarang, Makkad, Ramanpal Singh
• Format: Journal Article
• Language: English
• Published: India Medknow Publications & Media Pvt. Ltd 01.07.2024; Wolters Kluwer - Medknow; Wolters Kluwer Medknow Publications
• Subjects: Clinical outcomes; DNA methylation; Genetic analysis; Genetic markers; Genomics; Lesions; Oral cancer; oral potentially malignant disorders; Original Research; p53 Protein; Saliva; Genetic markers; oral potentially malignant disorders; oral cancer
• ISSN: 0976-4879; 0975-7406
• DOI: 10.4103/jpbs.jpbs_113_24

Genomic methylation being used as a sensitive indicator for identifying oral potentially malignant disorders (OPMDS) and oral cancer could be a viable option. DNA methylation is a potential approach for "cancer therapeutics" and can help researchers truly understand the genomic mechanism that leads to cancer. Investigation of genetic markers for predicting oral cancer progression and patient outcomes. One hundred and twelve patients having oral premalignant lesions and malignant lesions were included in this study. Saliva samples were obtained for analysis of the expression of genetic markers, such as p16, DAP-K, and MGMT. The Illumina Infinium HumanMethylation450 BeadChip (Illumina Inc., USA) would be used to assess genome-wide DNA methylation according to the manufacturer's instructions. Methylation of all the genes, that is, p16, DAP-K, and MGMT, was observed in 12.7% of oral cancer lesions. 41.94% of oral cancer lesions were found to have methylation of two genes. 13.23% cases were found to be associated with methylation of p16 and DAP-K, 12.12% cases were found to have methylation in the p16 and MGMT, and 15.27% cases of oral cancer lesions showed methylation of DAP-K and MGMT. Genetic markers, such as p53, DAP-K, and MGMT, can be used for predicting oral cancer progression and patient outcomes.